Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pelz

Showing results (741-750 of 835) with videos related to

Pageof 84
Sort By:
Annals of Intensive Care|September 15, 2023
Prognosis and management of acute symptomatic seizures: a prospective, multicenter, observational studyJulia Herzig-Nichtweiß, Farid Salih, Sascha Berning, et al.
Cancer Research|November 4, 2018
Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal AdenocarcinomaBrittany L Allen-Petersen, Tyler Risom, Zipei Feng, et al.
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Journal of Medicinal Chemistry|February 16, 2016
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based MethodsNicholas F Pelz, Zhiguo Bian, Bin Zhao, et al.
The Journal of Clinical Investigation|November 26, 2019
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneityTyler Risom, Xiaoyan Wang, Juan Liang, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)Friederike C Althoff, Horst-Dieter Hummel, Konrad Kokowski, et al.
Nature Communications|October 17, 2019
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancerKatherine A Michaelis, Mason A Norgard, Xinxia Zhu, et al.
Current Medical Research and Opinion|March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancerR Wuerstlein, K Sotlar, O Gluz, et al.
Radiology|January 21, 2025
CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)Dietrich Stoevesandt, Jonas Steglich, Jörg M Bartelt, et al.
Annals of Surgery|February 15, 2001
Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patientsC W Hendrix, J M Hammond, S M Swoboda, et al.
Pageof 84

Showing results (741-750 of 835) with videos related to

Sort By:
Pageof 84
Annals of Intensive Care|September 15, 2023
Prognosis and management of acute symptomatic seizures: a prospective, multicenter, observational studyJulia Herzig-Nichtweiß, Farid Salih, Sascha Berning, et al.
Cancer Research|November 4, 2018
Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal AdenocarcinomaBrittany L Allen-Petersen, Tyler Risom, Zipei Feng, et al.
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Journal of Medicinal Chemistry|February 16, 2016
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based MethodsNicholas F Pelz, Zhiguo Bian, Bin Zhao, et al.
The Journal of Clinical Investigation|November 26, 2019
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneityTyler Risom, Xiaoyan Wang, Juan Liang, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)Friederike C Althoff, Horst-Dieter Hummel, Konrad Kokowski, et al.
Nature Communications|October 17, 2019
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancerKatherine A Michaelis, Mason A Norgard, Xinxia Zhu, et al.
Current Medical Research and Opinion|March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancerR Wuerstlein, K Sotlar, O Gluz, et al.
Radiology|January 21, 2025
CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)Dietrich Stoevesandt, Jonas Steglich, Jörg M Bartelt, et al.
Annals of Surgery|February 15, 2001
Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patientsC W Hendrix, J M Hammond, S M Swoboda, et al.
Pageof 84